Mitogenic effects of phosphatidylcholine nanoparticles on MCF-7 breast cancer cells by Gándola, Yamila Belén et al.
Research Article
Mitogenic Effects of Phosphatidylcholine Nanoparticles on
MCF-7 Breast Cancer Cells
Yamila B. Gándola,1 Sebastián E. Pérez,2 Pablo E. Irene,1 Ana I. Sotelo,1
Johanna G. Miquet,1 Gerardo R. Corradi,1 Adriana M. Carlucci,2 and Lorena Gonzalez1
1 Instituto de Quı´mica y Fisicoquı´mica Biolo´gicas (UBA-CONICET), Facultad de Farmacia y Bioquı´mica, Junı´n 956,
1113 Buenos Aires, Argentina
2Departamento de Tecnologı´a Farmace´utica, Facultad de Farmacia y Bioquı´mica, Junı´n 956,
1113 Buenos Aires, Argentina
Correspondence should be addressed to Lorena Gonzalez; lgonza74@yahoo.com.ar
Received 20 December 2013; Revised 14 February 2014; Accepted 14 February 2014; Published 20 March 2014
Academic Editor: Leandro Rocha
Copyright © 2014 Yamila B. Ga´ndola et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Lecithins, mainly composed of the phospholipids phosphatidylcholines (PC), have many different uses in the pharmaceutical and
clinical field. PC are involved in structural and biological functions as membrane trafficking processes and cellular signaling.
Considering the increasing applications of lecithin-based nanosystems for the delivery of therapeutic agents, the aim of the present
work was to determine the effects of phosphatidylcholine nanoparticles over breast cancer cellular proliferation and signaling. PC
dispersions at 0.01 and 0.1% (w/v) prepared in buffer pH 7.0 and 5.0 were studied in the MCF-7 breast cancer cell line. Neutral 0.1%
PC-derived nanoparticles induced the activation of the MEK-ERK1/2 pathway, increased cell viability and induced a 1.2 fold raise
in proliferation. These biological effects correlated with the increase of epidermal growth factor receptor (EGFR) content and its
altered cellular localization. Results suggest that nanoparticles derived from PC dispersion prepared in buffer pH 7.0 may induce
physicochemical changes in the plasma membrane of cancer cells which may affect EGFR cellular localization and/or activity,
increasing activation of the MEK-ERK1/2 pathway and inducing proliferation. Results from the present study suggest that possible
biological effects of delivery systems based on lecithin nanoparticles should be taken into account in pharmaceutical formulation
design.
1. Introduction
Lecithins are amixture of phospholipids where phosphatidyl-
cholines are the main components (up to 98% w/w). Egg
or soy lecithin as well as purified phospholipids is used
for pharmaceutical purposes as dispersing, emulsifying, and
stabilizing agents included in intramuscular and intravenous
injectables or parenteral nutrition [1–3]. Lecithins have been
used to form liposomes, mixed micelles, and submicron
emulsions for pharmaceutical purposes. Moreover, aqueous
lecithin dispersions (water-lecithin-dispersion (WLD)) alone
or in combination with cationic molecules have been pro-
posed as carriers of lipophilic drugs and even as oligonu-
cleotides delivery systems for cancer treatment [4, 5]. Actu-
ally, nanoparticles designed from lecithin-in-water emulsions
were successfully used to deliver docetaxel to tumor cells
in vitro and even in a tumor model in mice [6]. Moreover,
lecithin-based nanoparticles have demonstrated to deliver
siRNA to breast cancer cells [7].
Phosphatidylcholines, the main components of lecithins,
are glycerophospholipids that incorporate choline as the head
group. The fatty acids bound to the glycerophosphatidic acid
can vary but generally one of them is unsaturated and the
other one is saturated. Phosphatidylcholine (PC) is a major
constituent of the cell membranes which is more commonly
found in the exoplasmic or outer leaflet of the plasma
membrane. PC also plays a role in membrane-mediated cell
signaling. The phospholipase D-mediated catabolism of PC
yields phosphatidic acid (PA) and choline, which are impor-
tant lipid second messengers involved in several signaling
pathways [8–10]. PA binds to Raf-1 and promotes its recruit-
ment to the plasma membrane where it is activated by direct
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interaction with Ras [11, 12]. Ras-mediated Raf-1 activation
leads tomitogen-activated protein kinase (MAPK) and PI3K/
Akt activation [13].Therefore, PA would have a pivotal role in
the amplification of signaling cascades required for survival
and growth [14]. PA also binds the mammalian target of
rapamycin (mTOR), a protein kinase that regulates cell cycle
progression and cell growth regulating several cellular events
like translation, transcription, membrane trafficking, and
protein degradation [15].
Phosphatidylcholine is also a substrate of the phosphati-
dylcholine-specific phospholipase C (PC-PLC). This enzyme
has been implicated in proliferation, differentiation, and
apoptosis of mammalian cells. PC-PLC-mediated hydrolysis
of PC yields PC-derived diacylglycerol (DAG) and phospho-
choline (P-chol) [8, 16]. DAG and P-chol, in turn, activate
a variety of kinases involved in cell proliferation, including
MAPKs, in different cell types [17, 18].
The lipid second messengers PA and DAG that are gener-
ated as a result of PLD and PC-PLC activity, respectively, can
also affect membrane trafficking, directly by altering mem-
brane curvature or indirectly by recruiting and/or activating
signaling mediators [19]. PLD-derived PA has been linked
to vesicular trafficking processes including Golgi transport,
endocytosis, and exocytosis [19]. Moreover, aberrant phos-
phatidylcholine metabolism in cancer cells was reported to
downmodulate the membrane expression of specific recep-
tors or proteins relevant for cell proliferation and survival
[20, 21]. Particularly, inhibition of phosphatidylcholine-
specific phospholipase C downregulates Human Epidermal
Growth Factor Receptor 2 (HER2) overexpression on plasma
membrane of breast cancer cells [21]. Likewise, membrane
phospholipid compositionwas demonstrated to affect epider-
mal growth factor receptor (EGFR) endocytosis [22]. Lipid
composition not only affects EGFR trafficking but also has
relevant regulatory effects on its kinase domain activation and
signaling [22, 23].
Membrane phospholipids as well as their fatty acid profile
are altered in tumor cells. The choline metabolite profile of
cancer cells is characterized by an elevation of phosphocho-
line and total choline-containing compounds. Indeed, total
cellular phosphatidylcholine (PC) can be used as a marker
for membrane proliferation in neoplastic mammary gland
tissues [24] or as a predictive biomarker formonitoring tumor
response [25].
Phosphatidylcholines are therefore not inert vehicles
but biological active compounds; phospholipids and their
derived second messengers are involved in cell proliferation
and trafficking, and the increase of phosphocholine and
choline-containing compounds has been described in tumor
cells. It has been recently highlighted that certain excipi-
ents have a role as active pharmaceutical components of
formulations because they can modify the pharmacological
activity of an active drug or produce biological effects [26].
Considering that phosphatidylcholines are the main com-
ponents of lecithins and taking into account the increasing
applications of lecithin-based formulations in nanomedicine
and for the delivery of antineoplastic agents, the aim of the
present work was to determine the biological effects of
phosphatidylcholine nanoparticles over breast cancer cell
signaling and proliferation.
2. Material and Methods
2.1. Reagents. Purified phosphatidylcholine from soybean
lecithin (Phospholipon 90G, CAS-number 97281-47-5) was
purchased from Lipoid (Ludwigshafen, Germany). Trizma
base,HEPES, Tween 20, TritonX-100, sodiumdodecyl sulfate
(SDS), glycine, ammonium persulfate, aprotinin, phenyl-
methylsulfonyl fluoride (PMSF), sodium orthovanadate, 2-
mercaptoethanol, Hoechst 33258, and BSA-fraction V were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
PVDF membranes, high performance chemiluminescence
film, and enhanced chemiluminescence- (ECL-) Plus are
from Amersham Biosciences (GE Healthcare, Piscataway,
NY, USA). Mini-Protean apparatus for SDS-polyacrylamide
electrophoresis, miniature transfer apparatus, acrylamide,
bis-acrylamide, and TEMED were obtained from Bio-Rad
Laboratories (Hercules, CA, USA). Anti-EGFR (1005) anti-
body and secondary antibodies conjugated with HRP were
purchased from Santa Cruz Biotechnology Laboratories
(Santa Cruz, CA, USA). Antibodies anti-phospho-mTOR
Ser2448, anti-mTOR, anti-p44/42 MAP kinase (ERK 1/2),
and anti-phospho-p44/42 MAP kinase Thr202/Tyr204 were
from Cell Signaling Technology Inc. (Beverly, MA, USA).
Cy3-conjugated secondary antibody against rabbit polyclonal
immunoglobulins was from Jackson ImmunoResearch Labo-
ratories, Inc. Bicinchoninic acid (BCA) protein assay kit was
obtained from Thermo Scientific, Pierce Protein Research
Products (Rockford, IL, USA).
2.2. Preparation of Phosphatidylcholine Nanoparticles. Dis-
persions of Phospholipon 90G 0.01 and 0.1% (w/v) in two
different diluents (66mM isotonic phosphate buffer pH 7.0
and 50mM isotonic acetate buffer pH 5.0) were prepared.
Bufferswere isotonized by adding sodiumchloridewhennec-
essary according to So¨rensen and White-Vincent methods.
Phosphatidylcholine was first dispersed in the appropriate
diluent with means of extensive mixing at 60∘C by use of a
thermostated magnetic stirrer in order to obtain good hydra-
tion.Next, the dispersionwas stirred for 2minutes at the same
temperature with a high-shearmixer (Ultra-Turrax T18 basic,
IKA Werke, Staufen, Germany) and sonicated at 20 kHz for
10 minutes. It was then sterilized by autoclaving (121∘C, 15
minutes).The sizes of the resulting particles in the dispersions
were determined by photon correlation spectroscopy (PCS)
using a Zetasizer (Malvern Nano ZS, Malvern Instruments
Ltd., UK). The zeta potential of the samples was measured
by the same instrument and the zeta potential values were
calculated according to Smoluchowski equation (Table 1). As
shown in Table 1, particles in the range of the nanometric size
were obtained.
2.3. Cell Culture. MCF-7 human breast cancer cell line was
obtained from the American Type Culture Collection
(ATCC) (Rockville, MD, USA). Cells were maintained in
Dulbecco’s minimum essential medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 50 𝜇g/mL genta-
mycine (Invitrogen, Life technology), and 2mML-glutamine
(Invitrogen, Life technology). Cells were cultured in 75 cm2
culture flasks at 37∘C in a humidified atmosphere of 5% CO
2
.
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Table 1: Effect of pH on the particle size and zeta potential of the
phosphatidylcholine nanoparticles.
Formulation Particle size (𝑑.nm) ± SD PdI Z-Pot (mV) ± SD
pH 5.0 232.7 ± 19.6 0.494 13.8 ± 2.1
pH 7.0 189.1 ± 11.9 0.544 −40.3 ± 3.0
𝑑.nm: diameter expressed in nm; PdI: polidispersion index.
Phosphatidylcholine (PC) nanoparticles were prepared in pH 5.0 and pH
7.0 buffers and analyzed by Dynamic Light Scattering (DLS). The size and
zeta potential of the particles were measured and reported as mean ± S.E.M.
(𝑛 = 4).
2.4. Culture Cells Treatment. To perform immunoblotting
assays, cells were seeded in clear 6-well plates (Corning
Costar, Fisher Scientific, USA) at a density of 300,000 cells/
well, while for immunofluorescence assays cells were seeded
at a density of 20,000 cells/well in covers placed in 24-well
plates. Phosphatidylcholine nanoparticles at 0.1 and 0.01%
were added in the presence or absence of serum. Cells were
further incubated at 37∘C for 24 hours in a 5% CO
2
atmo-
sphere. After incubation, cells were washed with phosphate
saline buffer and dishes were kept at −80∘C until cell solubi-
lization to prepare cells extracts, while covers were immedi-
ately processed for specific immunofluorescence labeling.
2.5. Preparation of Cell Extracts and Immunoblotting. Cells
were homogenized in buffer composed of 1% v/v Triton,
0.1M Hepes, 0.1M sodium pyrophosphate, 0.1M sodium
fluoride, 0.01M EDTA, 0.01M sodium vanadate, 0.002M
PMSF, and 0.035 trypsin inhibitory units/mL aprotinin (pH
7.0) at 4∘C. Cell homogenates were centrifuged at 15,000×g
for 40 minutes at 4∘C to remove insoluble material. Protein
concentration of supernatants was determined by the BCA
protein assay kit. Equal protein aliquots of solubilized cells
were diluted in Laemmli buffer, boiled for 5 minutes, and
stored at −20∘C until electrophoresis.
Samples were subjected to electrophoresis in SDS-poly-
acrylamide gels. Electrotransference of proteins from gel to
PVDF membranes and incubation with antibodies were per-
formed as already described [27]. Immunoreactive proteins
were revealed by enhanced chemiluminescence. Band inten-
sities were quantified using Gel-Pro Analyzer 4.0 software
(Media Cybernetics, Silver Spring, MD, USA).
To reprobe with other antibodies, the membranes were
washed with acetonitrile for 10 minutes and then incubated
in stripping buffer (2% w/v SDS, 0.100M 2-mercaptoethanol,
0.0625M Tris/HCl, pH 6.7) for 40 minutes at 50∘C while
shaking, washedwith deionizedwater, and blockedwith BSA.
2.6. Cell Viability Assay. Cells were seeded in clear 96-well
plates (Corning Costar, Fisher Scientific, USA) at a density
of 10,000 cells/well. Phosphatidylcholine at 0.1 and 0.01% was
added in 100 𝜇L of medium in the presence or absence of
serum. Cells were further incubated at 37∘C for 24 and 48
hours in a 5% CO
2
atmosphere. After incubation with the
phosphatidylcholine nanoparticles, cell number was evalu-
ated using the CellTiter 96 aqueous nonradioactive cell pro-
liferation assay (Promega, Madison, WI, USA). Triplicates
were run for each treatment. Values were expressed in terms
of percent of untreated control cells.
2.7. BrdU Incorporation Assay. DNA synthesis in proliferat-
ing cells was determined by measuring BrdU incorporation
with a BrdU ELISA assay [28]. For this purpose, the cells
were seeded in 96-well culture plates at a density of 10,000
cells/well. Phosphatidylcholine nanoparticles at 0.1 and 0.01%
were added in 100 𝜇L of medium in absence of serum. Cells
were further incubated at 37∘C for 48 hours in a 5% CO
2
atmosphere. BrdU (0.01M final concentration) was added to
the cells 16 hs before the end of incubation with PC nano-
particles. At the conclusion of labeling, cultures were rinsed
with phosphate buffered saline (PBS), pH 7.0, fixed with 70%
EtOH, denatured with 2M HCl (100𝜇L/well, 10 minutes,
37∘C), and neutralized with 0.1M Trizma buffer, pH 9. Cells
were then incubated with monoclonal anti-BrdU antibody
(50 𝜇L/well; 1 𝜇g/mL final; Roche, USA) at 37∘C for 60 min-
utes, washed with PBS, and incubated with goat anti-mouse
IgG horseradish peroxidase (HRP) conjugate at 37∘C for 30
minutes. Afterwards, cells were washed and labeling evi-
denced with tetramethylbenzidine (TMB). Triplicates were
run for each treatment. Values were expressed in terms of
percent of untreated control cells.
2.8. Immunofluorescence. Cells were washed twice in PBS,
pH 7.0, fixed in 2% formaldehyde in PBS for 10 minutes at
room temperature. After three washes with PBS (5 minutes
each), fixed cells were permeabilized with 0.5% Triton X-100
in PBS for 15minutes and incubated in blocking solution (10%
FBS in PBS) for 30 minutes to decrease nonspecific binding
of the antibodies. Cells were then incubated for 1 hour
at 37∘C with anti-EGFR, then washed, and incubated with
Cy3-conjugated secondary antibody against rabbit polyclonal
immunoglobulins. After a final washing step (3washes 5min-
utes each in PBS), cells were incubated with Hoechst 33258
(2 𝜇g/mL) for ten minutes. Finally, covers were mounted on
glass slides and fluorescence stained cells were imaged by
epifluorescent microscopy on a Leica DM2000 with a ×40
objective (Numerical Aperture =0.65) or by an Olympus Flu-
oview FV1000 spectral laser scanning confocal microscope
with a ×60 oil immersion objective (Numerical Aperture
=1.35) using dual excitation (473 nm for Cy3 and 405 nm for
Hoesch). At least 10 fields were examined and representative
images were photographed.
2.9. Statistical Analysis. Experiments were performed ana-
lyzing the phosphatidylcholine dispersions and vehicle (con-
trol) in parallel, 𝑛 representing the number of different
experiments. Results are presented as mean ± S.E.M. Statis-
tical analyses were performed by ANOVA followed by the
Newman-Keuls Multiple Comparison Test using the Graph-
Pad Prism 4 statistical program by GraphPad Software, Inc.
(San Diego, CA, USA). Data were considered significantly
different if 𝑃 < 0.05.
3. Results
3.1. Phosphatidylcholine Nanoparticles Activate Cell Signaling
Molecules Involved in Cell Proliferation. Previous results from
our research group have demonstrated that nanoparticles
prepared from phosphatidylcholine dispersed at 0.01 and
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0.1% (w/v) in buffer pH 5.0 and buffer pH 7.0 are able to bind
oligonucleotides and deliver them to breast cancer cells [7].
To determine oligonucleotide internalization, transfection
experiments were performed either in absence or presence of
serum and after a 24-hour incubation period [7]. That study
suggested that lecithin-based delivery systems might repre-
sent feasible novel formulations for anticancer gene therapies.
However, phosphatidylcholines, the main components of
lecithin, are involved in several biological processes like cell
proliferation and dynamics of the cell membrane. To ascer-
tain if PC nanoparticles have per se promitogenic activity,
the effects of phosphatidylcholine-based nanoparticles over
signal transduction pathways involved in cell proliferation
and survival were studied in the previously described exper-
imental conditions [7]. Considering that PC-derived second
messengers are involved in the activation of cellular signaling
mediators like mTOR and MAPKs [9, 29, 30], activation
of the Akt-mTOR and MEK1/2-ERK1/2 signaling pathways
by phosphatidylcholine was analyzed in the MCF-7 breast
cancer cell line.
3.1.1. Akt and mTOR Phosphorylation and Protein Content.
Akt is activated bymany types of cellular stimuli and regulates
fundamental cellular functions such as transcription, trans-
lation, proliferation, growth, and survival. Its dysregulation
has been associated with the development of diseases such as
cancer [31, 32]. Akt phosphorylation and protein content of
MCF-7 cells previously treated with aqueous phosphatidyl-
choline dispersions were analyzed by western blotting. Akt
phosphorylation at Ser473, an activating residue, was not
statistically different in control and treated cells neither in
absence (Figure 1(a)) nor in presence (Figure 1(b)) of serum.
Incubation with phosphatidylcholine had no effects on Akt
protein content fromMCF-7 cells (Figures 1(a) and 1(b)).
Mammalian target of rapamycin complex is a Ser/Thr
kinase of the phosphatidylinositol 3-kinase-related kinase
protein family. Akt phosphorylates and activates mTOR, thus
inducing protein synthesis and cell growth [15, 33]. mTOR
activation and protein content were studied by western blot-
ting in cells treated with phosphatidylcholine nanoparticles
(Figures 1(c) and 1(d)). Resembling the results obtained for
Akt, mTOR phosphorylation was not induced by PC either in
absence or in presence of serum, even when cells were incu-
bated with the highest concentrations of phosphatidylcholine
dispersions (Figures 1(c) and 1(d)).
3.1.2. MEK and ERK 1/2 Phosphorylation and Protein Content.
TheRas/Raf/MEK/ERK cascade couples signals from cell sur-
face receptors to transcription factors, which can regulate cell
cycle progression, apoptosis, or differentiation [34]. This sig-
naling cascade is often activated in certain tumors by chro-
mosomal translocations, mutations in cytokine receptors, or
overexpression of wild type or mutated receptors.
MAPkinase kinase (MEK) is a dual-specificity kinase that
phosphorylates tyrosine and threonine residues on extracel-
lular-signal-regulated kinases 1 and 2 (ERK 1/2) [35]. Two
related genes encode MEK1 and MEK2. Under basal condi-
tions, MEK binds the inactive serine/threonine kinase ERK
and restricts it to the cytosol. The MEK/ERK complex disso-
ciateswhenMEK is activated andphosphorylates ERK,which
may then dimerize. An activated ERK dimer can regulate
targets in the cytosol and also translocate to the nucleuswhere
it phosphorylates a variety of transcription factors regulating
gene expression.
Phosphorylation of MEK1/2 and ERK1/2 was studied in
the MCF-7 cells incubated with PC nanoparticles. Results
showed that MEK1/2 and ERK1/2 phosphorylation was sig-
nificantly increased when cells were treated with phosphati-
dylcholine dispersed in pH 7.0 solution at high concentration
independently of the absence (Figures 2(a) and 2(c)) or pres-
ence (Figures 2(b) and 2(d)) of serum. PC nanoparticles dis-
persed in buffer pH 7.0 at low concentration (0.01%) showed
a slight tendency to stimulate ERK1/2 phosphorylation; how-
ever, this difference did not achieve statistical significance
(Figures 2(a) and 2(b)). MEK1/2 and ERK1/2 protein levels
did not vary either in absence or in presence of serum.
3.2. Phosphatidylcholine Nanoparticles Induce MCF-7 Cell
Proliferation. As it was previously mentioned, MEK1/2-ERK
1/2 signaling pathway is involved in cell growth and prolifer-
ation promotion, so the effects of phosphatidylcholine nano-
particles over breast cancer cell viability were studied. For
this purpose, MCF-7 cells were seeded in 96-well plates and
incubated during 24 hours (Figures 3(a) and 3(b)) or 48 hours
(Figures 3(c) and 3(d)) with phosphatidylcholine dispersed at
0.1 and 0.01% in the absence (Figures 3(a) and 3(c)) or pres-
ence (Figures 3(b) and 3(d)) of serum. Results showed that
only high concentration of PC nanoparticles dispersed in
buffer pH 7.0 significantly increased cell viability of MCF-7
breast cancer cells either in absence (Figures 3(a) and 3(c)) or
presence of serum (Figures 3(b) and 3(d)) at both time peri-
ods. Phosphatidylcholine dispersed in buffer pH 5.0 or in
buffer pH 7.0 at low concentration (0.01%) had moderate
effects on cell viability but results were not statistically sig-
nificant (Figure 3).
To ascertain if the increased cell viability induced by
phosphatidylcholine nanoparticles 0.1% at pH 7.0 was a con-
sequence of cell proliferation induction, BrdU incorpora-
tion assay was performed. Considering that the differences
between viability of basal cells and PC-treated cells were bet-
ter evidenced when cells were treated in the medium without
serum, BrdU incorporation was assessed after 48 hours of
treatment with phosphatidylcholine nanoparticles in absence
of serum. Results demonstrated that increased cell viability
correlated with increased incorporation of BrdU (Figure 4).
When fold induction of BrdU incorporation was calculated it
was observed that PC 0.1% at pH 7.0 induces a 20% increment
in cell proliferation (Figure 4(b)).
The effects of phosphatidylcholine 0.1% dispersed in
buffer pH 7.0 over MCF-7 cell proliferation correlated with
the increased phosphorylation levels observed for MEK 1/2
and ERK1/2. Results suggest that high concentration of phos-
phatidylcholine nanoparticles at pH 7.0 induces activation
of the MEK1/2-ERK1/2 pathway and cell proliferation of the
breast cancer cells.
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Figure 1: Akt and mTOR phosphorylation and protein content. MCF-7 breast cancer cells were incubated for 24 hs with PC nanoparticles
dispersed at 0.1 and 0.01% (w/v) in buffer pH5.0 and buffer pH7.0 or vehicle (Ct) in the absence ((a) and (c)) or presence ((b) and (d)) of serum.
Representative results of immunoblots with anti-Akt and anti-phospho-Akt S473 ((a) and (b)) and anti-mTOR and anti-phospho-mTOR
S2448 ((c) and (d)) are shown. Reprobing with anti-actin antibody demonstrated uniformity of protein loading in all lanes. Quantification of
phosphorylated proteins was performed by scanning densitometry and expressed as percent of values measured for control, nonstimulated
breast cancer cells (Ct). Data are expressed as the mean ± S.E.M. of the indicated number (𝑛) of different experiments. Statistical analysis was
performed by ANOVA.
3.3. EGFR Levels Are Increased in Breast Cancer Cells Treated
with High Concentration of Phosphatidylcholine Nanoparti-
cles. Molecular aspects of cell signaling are controlled by
receptor/ligand localization and trafficking [36, 37]. Endocy-
tosis and subsequent delivery of endosomal cargos to lyso-
somes are essential for the degradation of many membrane-
associated proteins [38–40]. This process determines the
amplitude of growth factor signaling, and it is therefore
tightly regulated.
As previously mentioned, PC and second messengers
derived from these phospholipids are fundamental compo-
nents of the cell membrane and affect its dynamics and pro-
tein trafficking. Particularly, previous studies have demon-
strated that phospholipid membrane composition affects
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Figure 2: ERK1/2 and MEK1/2 phosphorylation and protein content. MCF-7 breast cancer cells were incubated for 24 hs with PC
nanoparticles dispersed at 0.01 and 0.01% (w/v) in buffer pH 5.0 and buffer pH 7.0 or vehicle (Ct) in absence ((a) and (c)) or presence
((b) and (d)) of serum. Representative results of immunoblots with anti-p44/42 MAP kinase (ERK1/2) and anti-phospho-p44/42 MAP
kinase Thr202/Tyr204 ((a) and (b)) and anti-MEK1/2 and antiphospho MEK ((c) and (d)) are shown. Reprobing with anti-actin antibody
demonstrated uniformity of protein loading in all lanes. Quantification of phosphorylated proteins was performed by scanning densitometry
and expressed as percent of valuesmeasured for control, nonstimulated breast cancer cells (Ct). Data are expressed as themean± S.E.M. of the
indicated number (𝑛) of different experiments. Statistical analysis was performed by ANOVA. Different letters denote significant difference
at 𝑃 < 0.05, whereas results with the same letter are not statistically different from each other.
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Figure 3: Viability of MCF-7 breast cancer cells incubated with phosphatidylcholine (PC) nanoparticles. Breast cancer cells were incubated
for 24 hours ((a) and (b)) and 48 hours ((c) and (d)) with PC nanoparticles dispersed at 0.01 and 0.1% (w/v) or vehicle (Ct) in buffer pH
5.0 and buffer pH 7.0 in the absence ((a) and (c)) or the presence ((b) and (d)) of serum. After incubation, cell viability was evaluated using
the CellTiter 96 aqueous nonradioactive cell proliferation assay (Promega). Triplicates were run for each treatment. Values were expressed in
terms of percent of untreated control cells set as 100%. Data are expressed as the mean ± S.E.M. of the indicated number (𝑛) of independent
experiments. Statistical analysis was performed by ANOVA. Different letters denote significant difference at 𝑃 < 0.05, whereas results with
the same letter are not statistically different from each other.
EGF receptor endocytosis and signaling [22, 23]. When puri-
fied EGFR was reconstituted into proteoliposomes of specific
lipid compositions, the lipid environment did not affect EGF
binding but EGFR tyrosine kinase function was indeed mod-
ified [23]. Moreover, mutants in the Drosophila phosphocho-
line cytidylyltransferase 1 (CCT1), the rate-limiting enzyme in
PC biosynthesis, result in altered phospholipid composition
of cell membranes and affect the endocytic pathway of EGFR
[22].
Endosomal trafficking of EGFR is crucial for determining
the amplitude and duration of EGFR signaling. Actually,
endocytosis of the EGFR is required for EGF-induced MAP
kinase activation. This was evidenced in experiments in
which EGF induction of MAPKs was reduced in dynamin
mutant cells which showed defects in clathrin-dependent
receptor-mediated endocytosis [41]. Treatment of breast can-
cer cells with high concentration of phosphatidylcholine
nanoparticles could affect membrane composition and con-
sequently trafficking of EGFR and signaling throughMAPKs.
Therefore, EGFR levels were determined by western blotting
and EGFR cellular localization was studied by immunofluo-
rescence of cells treated with the PC nanoparticles.
Results showed that EGFR levels increased when cells
were treated with PC nanoparticles dispersed in buffer pH 7.0
at high concentration both in absence or presence of serum
(Figures 5(a) and 5(b)). Afterwards, immunofluorescence
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Figure 4: Proliferation of MCF-7 breast cancer cells incubated with phosphatidylcholine (PC) nanoparticles. Breast cancer cells were
incubated for 48 hours with PC nanoparticle prepared in buffer pH 7.0 at 0.01 and 0.1% (w/v) or vehicle (Ct) in the absence of serum (a).
Proliferation was determined by measuring BrdU incorporation with a BrdU ELISA. Triplicates were run for each treatment. Values were
expressed in terms of percent of untreated control cells set as 100% (a). Data are expressed as the mean ± S.E.M. of the indicated number
(𝑛) of independent experiments. Fold induction with respect to control was calculated (b). Statistical analysis was performed by ANOVA.
Different letters denote significant difference at 𝑃 < 0.05, whereas results with the same letter are not statistically different from each other.
studies were conducted to ascertain the cellular localization
of increased EGFR in cells treated with PC 0.1% in pH 7.0. For
comparison, EGFR-immunofluorescence was performed in
control and phosphatidylcholine-treated cells. Observation
of stained cells by epifluorescence microscopy showed that
EGFR was uniformly distributed in control cells, while a sig-
nificant proportion of PC-treated cells showed an increase
in perinuclear EGFR staining (Figure 5(c)). However, PC-
treated cells exhibited an increased percentage of rounded
cells which might account for an increased proliferation rate.
These morphological changes could explain the pattern of
EGFR labeling observed when analyzed by epifluorescent
microscopy. Therefore, confocal microscopy studies were
performed to analyze possible alterations in EGFR cellular
localization produced by treatment with PC nanoparticles
(Figure 6). According to images obtained by epifluorescent
microscopy, a significant proportion of PC-treated cells
showed increased nuclear and perinuclear distribution of the
EGFR (Figure 6).
4. Discussion
Despite the multiple and different uses of lecithin with phar-
maceutical and therapeutic purposes, the possible biological
consequences of phosphatidylcholine administration should
be considered. They are important phospholipids involved
not only in structural functions in the cell but also in
membrane trafficking processes and signaling. Moreover,
increased levels of phosphocholine and choline-containing
compounds have been associated with progression and bad
prognosis of tumors. Considering the increasing use of
lecithin-based formulations for the delivery of antineoplastic
agents, the biological effects of nanoparticles derived from
aqueous phosphatidylcholine dispersions over breast cancer
cells proliferation and signaling were studied. Previously
characterized phosphatidylcholine nanoparticles proposed as
oligonucleotide delivery systems were used for that purpose
[7]. Results showed that PC nanoparticles prepared in neutral
buffer induced the activation of the MEK-ERK1/2 pathway
and increased cell viability and proliferation of the MCF-
7 breast cancer cell line. In accordance, Erk1/2 activation
by phosphatidylcholine liposomes has been described to
mediate neuronal differentiation [42, 43].
Incubation with the phosphatidylcholine nanoparticles
prepared in neutral buffer was associated with increased
EGFR content in the cancer cells and with its altered cellular
localization. High phosphatidylcholine concentrations might
induce physicochemical changes in the plasma membrane
that affect receptor trafficking and turnover. Moreover, a
process has been recently described, dependent on sustained
stimulation of cPCK and PLD activities, that leads to EGFR
sequestration near the perinuclear region, in the pericentrion
[44]. Accumulation of EGFR, reflected by increased EGFR
content and perinuclear localization of the receptor, would
result in increased activation of ERK1/2 and increased cell
proliferation. Besides interfering with EGFR trafficking, PC
nanoparticles might also have effects over EGFR activity [22,
23, 45]. Ligand-independent dimerization of EGFR occurs
with reasonable frequency; however, it is not activated until
the binding of the ligand. An autoinhibitory mechanism
involving the EGFR C-terminal tail would explain the lack of
activity of the dimer [45]. Interaction of phosphatidylcholine
nanoparticles with inactive EGFR dimers could be proposed
as a possible mechanism that disables such regulatory mech-
anisms and leads to EGFR activation even in absence of the
specific ligand. Moreover, activation of the dimer involves
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Figure 5: EGFR protein content and immunocytochemistry. MCF-7 breast cancer cells were incubated for 24 hours with PC nanoparticles
dispersed at 0.1 and 0.01% (w/v) in buffer pH 5.0 and buffer pH 7.0 or vehicle (Ct) in absence (a) or presence (b) of serum for immunoblot
studies, but only with PC dispersions at 0.1%, pH 7.0, or vehicle (control) in absence of serum for immunocytochemistry (c). Western blotting
was performed as described in M &M. Membranes were reprobed to asses actin content and demonstrate equal protein loading in all lanes.
Representative immunoblots are shown ((a) and (b)). EGFR quantificationwas performed by scanning densitometry and expressed as percent
of values measured for control, nonstimulated breast cancer cells. Data are expressed as the mean ± S.E.M. of the indicated number (𝑛) of
independent experiments. Statistical analysis was performed by ANOVA. Different letters denote significant difference at 𝑃 < 0.05, whereas
results with the same letter are not statistically different from each other. For EGFR immunocytochemistry (c), cells were washed, fixed,
permeabilized, blocked, and incubated with the anti-EGFR antibody, the Cy3-conjugated secondary antibody, and Hoechst. Finally covers
were mounted and examined by epifluorescence microscopy. Representative merged images of control and PC-nanoparticles-treated cells are
shown (c).
reorganization of hydrophobic regions of the EGFR [46];
nanoparticles obtained from dispersed PC at buffer pH 7.0
might favor such reorganization facilitating the formation of
the active conformation.
Increased concentration of phosphatidylcholine nano-
particles dispersed in buffer pH 7.0 had significant effects over
cell proliferation, EGFR levels, and activation of theMEK1/2-
ERK1/2 pathways; however, such effects were not observed
for PC nanoparticles dispersed in pH 5.0 buffer. The main
differences between both PC preparations is the charge
associated with the particles (zeta potential) (Table 1) and the
final adopted form [7], while the size of the particles did
not show important differences (Table 1). The nanoparti-
cles were in the range of 180–250 nm for all the studied
conditions (Table 1). At pH 5.0, small, isolated particles
with irregular shape were observed while at pH 7.0 more
elongated, locally cylindrical structures were described [7].
As expected, the zeta potential of the particles was positive
when using pH 5.0 buffer as diluent and negative when using
pH 7.0 buffer (Table 1). This fact can be related to changes
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field are shown.
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in the proportion of the differently charged forms of the
zwitterionic phosphocholine polar head within the selected
pH range and the conformational organization themolecules
acquire as a result.
In spite of the studies accomplished using lipid-based
nanocarriers for drug and gene delivery, the relationship
between their physicochemical characteristics and activation
of membrane receptors remains as an area of knowledge
with incipient development. In this regard, cationic liposomal
lipids have been described to modify cellular pathways and
stimulate immune or anti-inflammatory responses [47].
However, the mechanisms responsible for those biological
effects are poorly understood. Contrary to previous reports
concerning cationic lipids, the present study shows that bio-
logical effects are induced when cells are incubated with the
negatively charged phosphatidylcholine nanoparticles but
not when positively charged PC nanoparticles are admin-
istrated. Nevertheless, the mechanisms involved could be
similar to that proposed for cationic lipids; insertion of a
negatively charged phospholipid-derived nanoparticle in the
biological membrane might modify the lipid environment
of membrane proteins, the lipid-protein interaction and,
therefore, membrane functioning.
5. Conclusion
Results from the present study suggest that high phos-
phatidylcholine concentrations, assembled in negatively
charged nanoparticles, may induce physicochemical changes
in the plasma membrane that affect EGFR cellular localiza-
tion and/or its activity, therefore facilitating accumulation of
the receptor in the cytoplasm, which would be associated
with increased activation of the MEK-ERK1/2 pathway and
induction of cell cycle progression. It is interesting that the
described effects were specifically observed for the phos-
phatidylcholine nanoparticles prepared in pH 7 buffer but
not at pH 5; so we propose that this might be related to
the different net charge and morphology associated with
the particles, as no significant differences in size between
nanoparticles obtained fromdispersion at pH7.0 and 5.0were
observed. Considering that the PC nanoparticles preformed
in a pH 5.0 buffer showed no significant biological effects
over the breast cancer cells, these would be safer than those
prepared in a pH 7.0 buffer to deliver antimitotic agents.
The interpretation of the interaction between nanocar-
riers with membrane receptors is a matter that must be
elucidated for a more appropriate understanding of the bio-
logical effects that are promoted.The present study highlights
the importance of the research on the effects of vehicles
broadly used in the pharmaceutical area and demonstrates
that possible biological effects of formulations based on
phosphatidylcholine nanoparticles should be considered.
Moreover, studies about the possible biological action of PC
nanoparticles on normal cells would be useful to expand
our knowledge about their potential pharmaceutical uses.
Excipient effects over normal physiology and cell biology
represent important factors to be concerned about in rational
formulation design.
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